Why Glycosylation Control Is No Longer a Secondary Concern in the Development of Complex Biologics

The development of advanced biologic therapeutics, such as bispecific antibodies, antibody-drug conjugates, Fc-fusion proteins, and advanced immunotherapies, is increasingly sensitive to glycosylation heterogeneity. Traditional monoclonal antibodies (mAbs) were historically managed with downstream glycosylation control, but modern complex biologics demand upstream glycosylation control.

Glycosylation issues in newer therapeutics can significantly impact therapeutic efficacy, batch-to-batch consistency, and batch rejection. Therefore, glycosylation control must be a priority right from the beginning of cell line and process development.

Contract development and manufacturing organizations (CDMOs) are adapting to this shift, shifting their focus to upstream glycosylation control using quality-by-design (QbD) methodologies. The complexity of newer biologics necessitates proactive upstream glycosylation control, which helps maintain process consistency, strengthens regulatory submissions, and reduces the risk of batch failures or regulatory delays.

Glycosylation variability is often clone-dependent, making clone selection an essential step in glycosylation control strategies. Early assessment of glycosylation-related quality attributes, such as fucosylation levels, galactosylation patterns, and sialic acid linkage profiles, based on the molecule's intended mechanism of action and functional requirements, can help developers eliminate unsuitable clones early in the development process.